These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12058881)

  • 1. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
    Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
    Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
    AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
    Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
    Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.
    Günel N; Coşkun U; Toruner FB; Sancak B; Yilmaz E; Cengiz O; Elbeg S; Uner A; Ozkan S
    Curr Med Res Opin; 2003; 19(1):47-50. PubMed ID: 12661780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate.
    Ogawa Y; Murata Y; Saibara T; Nishioka A; Kariya S; Yoshida S
    Oncol Rep; 2003; 10(5):1473-8. PubMed ID: 12883726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
    Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
    Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
    Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
    Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen-induced fatty liver in patients with breast cancer.
    Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
    Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
    [No Abstract]   [Full Text] [Related]  

  • 15. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug-induced Nonalcoholic Steatohepatitis].
    Miyamura M; Yokota J; Saibara T
    Yakugaku Zasshi; 2016; 136(4):579-82. PubMed ID: 27040342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
    Ahmed MH; Osman KA
    Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.